¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"platelet tissue factor"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
¿µ¹® osseous tissue ÇÑ±Û »ÀÁ¶Á÷, °ñÁ¶Á÷
¼³¸í   
  °ñ¼¼Æ÷¿Í °ñ¼¼Æ÷ÁÖÀ§ÀÇ µüµüÇÑ Ä®½·Á¶Á÷À¸·Î µÑ·¯½ÎÀΠ¹ÐÁýµÈ °áÇÕÁ¶Á÷À» ¶æÇÑ´Ù. ÀÌ °ñÁ¶Á÷¿¡ ÀÇÇØ¼­ »À°¡ ÀÌ·ç¾îÁ® ÀÎüÀÇ °ñ°ÝÀ» Çü¼ºÇÑ´Ù.
¿µ¹® epithelial tissue ÇÑ±Û »óÇÇÁ¶Á÷
¼³¸í   
  »óÇǴ ÇÑ Ãþ ¶Ç´Â ¿©·¯ ÃþÀÇ ¼¼Æ÷·Î ÀÌ·ç¾îÁø ÆÇ ¸ð¾çÀÇ ±¸Á¶·Î ½ÅüÀǠǥ¸é°ú °ü»ó±¸Á¶ÀÇ ³»°­À» µÑ·¯½Î°í ÀÖ´Ù. »óÇǼ¼Æ÷¿Í »óÇǼ¼Æ÷»çÀÌÀÇ ÀûÀº ¾çÀ¸·Î Á¸ÀçÇÏ¿© »óÇÇ»çÀÌÀÇ °ø°£À» Ã¤¿ì°í Àִ ¼¼Æ÷°£ÁúÀ» ÇÕÃÄ »óÇÇÁ¶Á÷À̶ó ÇÑ´Ù. »óÇÇÁ¶Á÷¿¡´Â ¿øÄ¢ÀûÀ¸·Î Ç÷°üÀÌ ºÐÆ÷µÇ¾î ÀÖÁö ¾Ê´Ù.
¿µ¹® granulation tissue ÇÑ±Û À°¾ÆÁ¶Á÷
¼³¸í   
  ¸ð¼¼Ç÷°üÀ̠dzºÎÇϸ砿ռºÇϰԠÁõ½ÄÀ» °è¼ÓÇϴ ¾î¸° °áÇÕÁ¶Á÷. Ã¢»ó µî Á¶Á÷ °á¼Õ¿¡ ´ëÇÑ ¼öº¹, À̹°Ã³¸®ÀÇ ±âÁúÈ­, ¿°ÁõÀÌ ¸¸¼ºÀûÀΠ°æ°ú¿¡ Àְųª Á¾¾çÁõ½Ä¿¡ µ¿¹ÝµÈ »çÀ̹°ÁúÀÇ ¹ÝÀÀ¼º ¿°Áõ¿¡¼­ °üÂûµÈ´Ù. ±¸¼º¼ººÐÀº »ý±äÁö ¾ó¸¶ ¾ÈµÇ´Â ¾î¸° À°¾ÆÁ¶Á÷Àº ¼¶À¯¸ð¼¼Æ÷ÀÇ Áõ½Ä, »õ·Î »ý±ä ¸ð¼¼Ç÷°ü°ú ¿©·¯ À¯ÁÖ¼¼Æ÷ ¹× ´Ù¸¥ Áß°£¿±¼¼Æ÷(¹éÇ÷±¸, ¸²ÇÁ±¸, ÇüÁú¼¼Æ÷, Á¶Á÷±¸, ´ÜÇÙ±¸, °Å´ë¼¼Æ÷)µîÀ¸·Î ±¸¼ºµÈ´Ù. À̰ÍÀÌ ½Ã°£ÀÌ Áö³ª ±×¸®µÇ¸é, ¸ð¼¼Ç÷°ü°ú À¯ÁÖ¼¼·Î, ´Ù¸¥Á¶Á÷¼ººÐÀ» °¨¼Ò½ÃÄÑ ¸¸¼ºÈ­ÇÏ¿© ¿À·¡µÈ À°¾Æ°¡ µÇ¸ç °á±¹Àº ¼¶À¯¼¼Æ÷¿Í ¾Æ±³Áú¼¶À¯·Î ±¸¼ºµÈ ¹ÝÈçÁ¶Á÷À¸·Î º¯ÇÑ´Ù.
¿µ¹® tissue ÇÑ±Û Á¶Á÷
¼³¸í   
  Æ¯Á¤ ±¸Á¶¿Í ±â´ÉÀ» °®´Â ¼¼Æ÷ Áý´Ü. ¼¼Æ÷ »çÀÌ¿¡´Â ´Ù¼Ò°£ ¼¼Æ÷°£ÁúÀÌ µé¾î ÀÖ´Ù. ¼¼Æ÷°£Áú¿¡´Â ±Û¸®ÄÚ»ç¹Ì³ë±Û¸®Ä­, È÷µå·Ï½Ã¾ÆÆÄŸÀÌÆ®¿Í °°Àº ±âÁú°ú ¾Æ±³Áú¼¶À¯¿Í °°Àº ¼¶À¯°¡ ¹ß°ßµÈ´Ù. Á¶Á÷¼º»óÀº ±¸¼º¼¼Æ÷¿Í ¼¼Æ÷°£ÁúÀÇ Á¾·ù¿Í ¾ç¿¡ ÀÇÇØ °áÁ¤µÈ´Ù. Á¶Á÷Àº »óÇÇÁ¶Á÷, ÁöÁöÁ¶Á÷, ±ÙÀ°Á¶Á÷, ½Å°æÁ¶Á÷À¸·Î ´ëº°µÇ¸ç, »óÇÇÁ¶Á÷Àº ¼¼Æ÷°£ÁúÀ» °ÅÀÇ °®Áö ¾ÊÀ¸¸ç, ÁöÁöÁ¶Á÷Àº °áÇÕÁ¶Á÷À̳ª »ÀÁ¶Á÷°ú °°ÀÌ ¼¼Æ÷°£ÁúÀ̠dzºÎÇÑ °ÍÀÌ ¸¹´Ù.
¿µ¹® tissue biopsy ÇÑ±Û Á¶Á÷»ý°Ë
¼³¸í   
  È¯ÀÚÀÇ º´ÀûÀΠÁ¶Á÷ÀÇ ÀϺθ¦ ¶¼¾î ³»¼­ º´¸®Á¶Á÷Ç¥º»À» ¸¸µé¾î¼­ Çö¹Ì°æÀûÀ¸·Î °Ë»çÇϴ °Í. ¿Ü°úÀû ¼ö¼úÀç·á·ÎºÎÅÍ º´¸®Á¶Á÷ÇÐÀû °Ë»ç¸¦ ÇÏ¿© »ýü³»ÀÇ º´º¯À» Ãß±¸Çϴ ºÐ¾ß¸¦ ¿Ü°úº´¸®ÇÐÀ̶ó°í ÇÑ´Ù. »ý°Ë¿¡´Â ½û±â»ý°Ë, ÃµÀÚħ»ý°Ë, ²ç¶Õ±â½Ä»ý°Ë, ³»½Ã°æ»ý°Ë ¿Ü¿¡ ¼¼Æ÷ÁøÀ̶ó°í ºÒ¸®¿ì´Â ¹Ú¸®¼¼Æ÷ÁøÀ̳ª ¼¼Ã´¼¼Æ÷Áø µî ¶³¾îÁø ¼¼Æ÷¸¦ µµ¸»°Ë»çÇϴ ¹æ¹ýÀÌ Æ÷ÇԵȴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • areolar tissue
    ¼º±ÙÁ¶Á÷
  • adipose tissue
    Áö¹æÁ¶Á÷
  • compact tissue
    Ä¡¹ÐÁ¶Á÷
  • connective tissue
    °áÇÕÁ¶Á÷
  • connective tissue cell
    °áÇÕÁ¶Á÷¼¼Æ÷
  • connective tissue disease
    °áÇÕÁ¶Á÷º´
  • connective tissue fiber
    °áÇÕÁ¶Á÷¼¶À¯
  • connective tissue nevus
    °áÇÕÁ¶Á÷¸ð¹Ý
  • elastic tissue
    ź·ÂÁ¶Á÷
  • epithelial tissue
    »óÇÇÁ¶Á÷
  • erectile tissue
    ¹ß±âÁ¶Á÷
  • granulation tissue
    À°¾ÆÁ¶Á÷
  • gut-associated lymphatic tissue
    âÀÚ¿¬°ü¸²ÇÁÁ¶Á÷, À忬°ü¸²ÇÁÁ¶Á÷
  • hemopoietic tissue
    Ç÷±¸Çü¼ºÁ¶Á÷, Á¶Ç÷Á¶Á÷
  • interstitial tissue
    »çÀÌÁúÁ¶Á÷, °£ÁúÁ¶Á÷
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • nerve growth factor
    ½Å°æ¼ºÀåÀÎÀÚ
  • precipitation factor
    ÃËÁø¿äÀÎ
  • predisposing factor
    ¼±Çà¿äÀÎ
  • prognostic factor
    ¿¹ÈÄÀÎÀÚ
  • psychological factor
    ½É¸®¿ä¼Ò
  • relaxing factor
    ÀÌ¿ÏÀÎÀÚ
  • resistance factor
    ³»¼ºÀÎÀÚ, °ßµõÀÎÀÚ
  • rheumatoid factor
    ·ù¸¶Æ¼½ºÀÎÀÚ
  • risk factor
    À§ÇèÀÎÀÚ
  • transforming growth factor
    Àüȯ¼ºÀåÀÎÀÚ
  • vascular endothelial growth factor
    Ç÷°ü³»ÇǼºÀåÀÎÀÚ
  • tissue plasminogen activator
    Á¶Á÷Çö󽺹̳ë°ÕȰ¼ºÁ¦
  • mixed connective tissue disease
    È¥ÇÕ°áÇÕÁ¶Á÷º´
  • tissue
    Á¶Á÷
  • adipose tissue
    Áö¹æÁ¶Á÷
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • random donor platelet
    ´ÙÀÎÇåÇ÷Ç÷¼ÒÆÇ
  • single donor platelet
    ÀÏÀΰøÇ÷Ç÷¼ÒÆÇ, ÀÏÀÎÇåÇ÷Ç÷¼ÒÆÇ
  • acute normal tissue effect
    Á¤»óÁ¶Á÷±Þ¼º¿µÇâ
  • adipose tissue
    Áö¹æÁ¶Á÷
  • tissue antibody
    Á¶Á÷Ç×ü
  • tissue biopsy
    Á¶Á÷»ý°Ë
  • compact tissue
    Ä¡¹ÐÁ¶Á÷
  • connective tissue
    °áÇÕÁ¶Á÷
  • connective tissue cell
    °áÇÕÁ¶Á÷¼¼Æ÷
  • connective tissue disease
    °áÇÕÁ¶Á÷º´
  • connective tissue fiber
    °áÇÕÁ¶Á÷¼¶À¯
  • connective tissue nevus
    °áÇÕÁ¶Á÷¸ð¹Ý
  • soft tissue coverage
    ¿¬Á¶Á÷ÇǺ¹
  • tissue characterization
    Á¶Á÷Ư¼º°¨º°
  • tissue conduction
    Á¶Á÷Àüµµ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • acute and late normal tissue effects
    Á¤»óÁ¶Á÷ ±Þ¼º¿µÇâ, Á¤»óÁ¶Á÷ ¸¸¼º ¿µÇâ
  • adipose tissue disease
    Áö¹æÁ¶Á÷Áúȯ.
  • angioblastic tissue
    Ç÷°ü¹ß»ýÁ¶Á÷
  • free water in stationary tissue
    Á¤Àû Á¶Á÷³» ÀÚÀ¯ ¼öºÐ
  • general connective tissue
    ÀϹݰáÇÕÁ¶Á÷.
  • gingival tissue esthetics
    Ä¡ÀºÁ¶Á÷½É¹Ì¼º.
  • granulation tissue
    À°¾ÆÁ¶Á÷(¡­ðÚòÄ)
  • gut-associated lymphatic tissue (GALT)
    Àå-¿¬°ü ¸²ÇÁÁ¶Á÷
  • hemopoietic tissue
    Ç÷__ü¼ºÁ¶Á__ Á¶Ç÷Á¶Á÷.
  • hemopoietic tissue
    Ç÷±¸Çü¼ºÁ¶Á÷
  • hemopoietic tissue
    Ç÷±¸Çü¼ºÁ¶Á÷, Á¶Ç÷Á¶Á÷.
  • hemopoietic tissue
    Ç÷¾×Çü¼ºÁ¶Á÷
  • immunity, tissue
    Á¶Á÷¸é¿ª
  • pigment connective tissue
    »ö¼Ò°áÇÕÁ¶Á÷
  • pigment tissue
    »ö¼ÒÁ¶Á÷(ßäáÈðÚòÄ).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • lupus erythematosus factor = LE factor
    È«¹Ý¼º ·çǪ½ºÀÎÀÚ(ûõÚèàõ¡­ì×í­)
  • time, dose and fractionation factor, TDF factor
    ½Ã°£¼±·®ºÐÇÒÀÎÀÚ
  • blood disc =b. platelet
    Ç÷¼ÒÆÇ(Ì´ËÛ̬).
  • blood platelet =thrombocyte
    Ç÷¼ÒÆÇ(úìá³÷ù).
  • direct platelet count
    Á÷Á¢Ç÷¼ÒÆÇ°è»ê(¹ý)(?Ì´ËÛ̬˭Ë×ËÑ).
  • granulocyte-platelet-lymphocyte antigens
    °ú¸³±¸Ç÷¼ÒÆÇ¸²ÇÁ±¸Ç׿ø
  • hellp(hemolysis, elevated liver enzymes, low platelet),heliminths
    À±Ãæ(ëÌõù)
  • hemorrhagic diathesis,defective platelet function
    Ç÷¼ÒÆÇ±â´É°á¼Õ(úìá³÷ùѦÒöÌÀáß)
  • human platelet antigens=HPA
    ÀÎÇ÷¼ÒÆÇÇ׿ø
  • mean platelet volume
    Æò±ÕÇ÷¼ÒÆÇ¿ëÀû
  • mean platelet volume=MPV
    Æò±ÕÇ÷¼ÒÆÇ¿ëÀû
  • platelet
    Ç÷¼ÒÆÇ
  • platelet
    Ç÷¼ÒÆÇ(úìá³÷ù).
  • platelet
    Ç÷¼ÒÆÇ(úìá³÷ù)
  • platelet adhesion
    Ç÷¼ÒÆÇºÎÂø
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Nervous tissue (Neuroblastoma)
    ½Å°æÁ¶Á÷ (½Å°æ¸ð¼¼Æ÷Á¾)
    [¿¾ ¿ë¾î] ½Å°æÁ¶Á÷
  • Cardiac muscular tissue
    ½ÉÀå±ÙÀ°Á¶Á÷
    [¿¾ ¿ë¾î] ½É±ÙÁ¶Á÷
  • Conducting tissue of heart
    ½ÉÀåÀüµµÁ¶Á÷
    [¿¾ ¿ë¾î] ½ÉÀåÀüµµ°è
  • Collagenous connective tissue
    ¾Æ±³°áÇÕÁ¶Á÷
    [¿¾ ¿ë¾î] ±³¿ø°áÇÕÁ¶Á÷
  • Cartilage tissue
    ¿¬°ñÁ¶Á÷ [¹°··»ÀÁ¶Á÷]
    [¿¾ ¿ë¾î] ¿¬°ñÁ¶Á÷
  • Submucosal tissue
    Á¡¸·¹ØÁ¶Á÷
    [¿¾ ¿ë¾î] Á¡¸·ÇÏÁ¶Á÷
  • Abnormality of tissue
    Á¶Á÷ÀÌ»ó
    [¿¾ ¿ë¾î] Á¶Á÷ÀÌ»ó
  • Notochordal tissue (Chordoma)
    ô»èÁ¶Á÷ (ô»èÁ¾)
    [¿¾ ¿ë¾î] ô»èÁ¶Á÷
  • Lamellar bone tissue
    ÃþÆÇ»ÀÁ¶Á÷
    [¿¾ ¿ë¾î] ÃþÆÇ¼º°ñÁ¶Á÷
  • Compact bone tissue
    Ä¡¹Ð»ÀÁ¶Á÷
    [¿¾ ¿ë¾î] Ä¡¹Ð°ñÁ¶Á÷
  • Dense collagenous connective tissue
    Ä¡¹Ð¾Æ±³°áÇÕÁ¶Á÷
    [¿¾ ¿ë¾î] Ä¡¹Ð°áÇÕÁ¶Á÷
  • Renal tissue (Nephroblastoma)
    ÄáÆÏÁ¶Á÷ (ÄáÆÏ¸ð¼¼Æ÷Á¾)
    [¿¾ ¿ë¾î] ½ÅÁ¶Á÷
  • Elastic connective tissue
    ź·Â°áÇÕÁ¶Á÷
    [¿¾ ¿ë¾î] ź·Â°áÇÕÁ¶Á÷
  • Prechondral tissue
    Dz¿¬°ñÁ¶Á÷
    [¿¾ ¿ë¾î] Àü¿¬°ñÁ¶Á÷
  • Subcutaneous tissue
    ÇǺιØÁ¶Á÷
    [¿¾ ¿ë¾î] ÇÇÇÏÁ¶Á÷
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • tissue hormone
    Á¶Á÷(ðÚòÄ)È£¸£¸ó
  • tissue plasminogen activator
    Á¶Á÷(ðÚòÄ)Çö󽺹̳ëÀü Ȱ¼ºÀÚ (üÀàõí­)
  • tissue polypeptide antigen
    Á¶Á÷(ðÚòÄ)Æú¸®ÆéŸÀ̵å Ç׿ø (ù÷ê«)
  • tissue slice
    Á¶Á÷ õ¿± (ðÚòÄô¼ç¨)
  • tissue-specific enzyme
    Á¶Á÷ ƯÀÌ È¿¼Ò (ðÚòÄ÷åì¶ý£áÈ)
  • tissue thromboplastin
    Á¶Á÷(ðÚòÄ)Æ®·Òº¸ÇÃ¶ó½ºÆ¾
  • white adipose tissue
    ÈØ Áö¹æÁ¶Á÷ (ò·Û¸ðÚòÄ)
  • acetate-replacing factor
    ¾Æ¼¼Æ®»ê(ß«)ġȯ ÀÎÀÚ(öÇüµì×í­)
  • achromotrichia factor
    ¸ð¹ß»ö¼Ò°áÇÌÀÎÀÚ (Ù¾Û¥ßäáÈÌÀù¹ì×í­)
  • angiogenic factor
    Ç÷°üÇü¼ºÀÎÀÚ(úìηû¡à÷ì×í­)
  • animal protein factor
    µ¿¹°´Ü¹éÁúÀÎÀÚ(ÔÑÚªÓ±ÛÜòõì×í­)
  • anti-egg-white injury factor
    Ç׳­¹é ¼Õ»óÀÎÀÚ(ù÷ÑëÛÜáßß¿ì×í­)
  • anti-fatty-liver-factor
    Ç×Áö¹æ°£ÀÎÀÚ(ù÷ò·Û¸ÊÜì×í­)
  • anti-gray-hair factor
    Ç×¹é¸ð¹ß ÀÎÀÚ(ù÷ÛÜÙ¾Û¥ì×í­)
  • antiacrodynia factor
    Ç×Áö´Üµ¿Åë ÀÎÀÚ(ù÷ò¶Ó®ÔÙ÷Ôì×í­)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • granulation tissue
    À°¾ÆÁ¶Á÷
  • inflammatory tissue
    ¿°ÁõÁ¶Á÷
  • interstitial tissue
    °£ÁúÁ¶Á÷
  • lattice in stationary tissue
    Á¤ÀûÁ¶Á÷³»°ÝÀÚ
  • MALT(mucosa associated lymphoid tissue)
    Á¡¸·°ü·Ã¸²ÇÁÁ¶Á÷
  • mesenchymal tissue
    Áß°£¿±Á¶Á÷, °£¿±Á¶Á÷
  • muscle tissue
    ±ÙÀ°Á¶Á÷, ±ÙÁ¶Á÷
  • osseous tissue
    »ÀÁ¶Á÷, °ñÁ¶Á÷
  • osteoblastic tissue
    °ñÇü¼ºÁ¶Á÷
  • proper connective tissue
    °íÀ¯°áÇÕÁ¶Á÷
  • pseudogating in flowing tissue
    À¯µ¿Á¶Á÷¿¡¼­ À§°ÔÀÌÆÃ
  • reticular connective tissue
    ¼¼¸Á°áÇÕÁ¶Á÷
  • reticular tissue
    ¼¼¸ÁÁ¶Á÷
  • retropharyngeal soft tissue space
    ÀεÎÈĺο¬ºÎÁ¶Á÷
  • scar tissue
    ¹ÝÈçÁ¶Á÷
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
EF ectopic focus; edema factor; ejection fraction; elastic fibril; electric field; elongation factor; e...
SF Sabin-Feldman [test]; safety factor; salt-free; scarlet fever; screen film; seminal fluid; serosal f...
PC avoirdupois weight [Lat. pondus civile]; packed cells; paper chromatography; paracortex; parent cell...
PFKP phosphofructokinase, platelet type; 6-phosphofructo-2-kinase, platelet type
PM after death (Lat. post mortem); after noon [Lat. post meridiem]; mean pressure; pacemaker; pantomogr...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
PDGFR Platelet Derived Growth Factor Receptors
PF 3 Platelet Factor 3
PF-4 Platelet Factor 4
PAFAH Platelet activating factor acetyl hydrolase
PAF Platelet activation factor
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • bone tissue
    »À Á¶Á÷, °ñ Á¶Á÷
  • bony tissue
    °ñ¼º Á¶Á÷
  • border tissue movement
    º¯¿¬ Á¶Á÷ ¿îµ¿
  • calcified tissue
    ¼®È¸È­ Á¶Á÷
    ¼®È¸È­°¡ ÀϾ Á¶Á÷.
  • cartilage tissue
    ¿¬°ñ Á¶Á÷, ¹°··»À Á¶Á÷
    »À ¸»´Ü¿¡ Àִ ź·Â¼º ÀÖ´Â °áÇÕÁ¶Á÷À̸ç, »À Ç¥¸éÀ» ½Ñ´Ù. ÅÂ¾Æ °ñ°Ý, ´Á°ñ, ºñ Áß°Ý, ¿ÜÀÌ¿¡µµ Á¸Àç.
  • cellular connective tissue
    ¼¼Æ÷¼º °áÇÕ Á¶Á÷
    ¼¼Æ÷·Î »çÀ̰¡ ¿¬°áµÇ¾î ÀÖ´Â Á¶Á÷.
  • cementoid tissue
    ¹é¾ÇÁú¾ç Á¶Á÷
  • chromaffin tissue
    Å©·Ò ģȭ Á¶Á÷
  • compact tissue
    Ä¡¹Ð Á¶Á÷
  • connective tissue
    °áÇÕÁ¶Á÷
    ´Ù¸¥ Á¶Á÷µéÀ» ÁöÁöÇÏ°í ¿¬°áÇϸç, ¿©·¯ ½Åü ±¸Á¶¹°À» ÁöÁöÇÏ´Â Á߹迱¼º Á¶Á÷À¸·Î¼­ ź¼º ¼¶À¯ °áÇÕÁ¶Á÷À̳ª ±³¿ø ¼¶À¯ °áÇÕÁ¶Á÷, °ñ Á¶Á÷°ú ¿¬°ñ Á¶Á÷À» Æ÷ÇÔÇÑ´Ù. °áÇÕ Á¶Á÷Àº ¿¬°ñÀ» Á¦¿ÜÇϰí´Â Ç÷°üÀÌ Ç³ºÎÇÏ´Ù.
  • connective tissue disease
    °áÇÕÁ¶Á÷ º´, °áÇÕÁ¶Á÷ Áúȯ
  • connective tissue fiber
    °áÇÕ Á¶Á÷ ¼¶À¯
  • connective tissue sheath of Key and Retzius
    Ű-·¹Ä¡¿ì½ºÀÇ °áÇÕ Á¶Á÷ ÃÊ
    ½Å°æ³»¸·, ƯÈ÷ ½Å°æ¼¶À¯ Á¾¸»Áö ÁÖÀ§ÀÇ ¾ãÀº ¿¬Àå.
  • degree of tissue pathology
    Á¶Á÷³» º´¼Ò Á¤µµ
  • dense connective tissue
    Ä¡¹Ð °áÇÕÁ¶Á÷
    ±³¿ø¼¶À¯°¡ dzºÎÇÏ°Ô °¡µæ Â÷ ÀÖ´Â °áÇÕÁ¶Á÷.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
platelet actomyosin The contractile protein of platelets, responsible for clot retraction, platelet aggregation, and release of ADP and other biologic amines essential to platelet function.
Synonym: thrombosthenin.
(05 Mar 2000)
platelet adhesiveness The process whereby platelets adhere to something other than platelets, e.g., collagen, basement membranes, microfibrils, or other "foreign" surfaces.
(12 Dec 1998)
platelet aggregation The attachment of platelets to one another. This clumping together can be induced by a number of agents (e.g., thrombin, collagen) and is part of the mechanism leading to the formation of a thrombus.
(12 Dec 1998)
platelet aggregation inhibitors Drugs or agents which antagonise or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.
(12 Dec 1998)
platelet aggregation test A test of the ability of platelets to adhere to each other and hence form a haemostatic plug to prevent bleeding; failure to aggregate occurs in several conditions, e.g., thrombasthenia, Von Willebrand's disease, and following administration of aspirin, phenylbutazone, and indomethacin; the test is conducted by quantitating the decrease in turbidity that occurs in platelet-rich plasma following the in vitro addition of one or several platelet-aggregating agents (e.g., ADP, epinephrine, or serotonin).
(05 Mar 2000)
platelet basic protein <protein> Protein that is the precursor of connective tissue activating peptide III and _ thromboglobulin.
(18 Nov 1997)
platelet cofactor I A coagulation (clotting) factor. Classic haemophilia (haemophilia A) is due to a congenital deficiency in the amount (or activity) of factor VIII. Factor VIII is also known as antihemophiliac factor (AHF) or antihemophiliac globulin (AHG). The gene for factor VIII (that for classic haemophilia) is on the X chromosome so females can be silent carriers without symptoms and males can be haemophiliacs.
(12 Dec 1998)
platelet cofactor II <chemical> Storage-stable blood coagulation factor acting in the intrinsic pathway. Its activated form, ixa, forms a complex with factor viii and calcium on platelet factor 3 to activate factor x to xa. Deficiency of factor ix results in christmas disease (haemophilia b).
Chemical name: Blood-coagulation factor IX
(12 Dec 1998)
platelet count <haematology> The number of platelets per cubic millimetre of blood. The normal range is 150,000-400,000 platelets per cubic mm. Platelet counts under 10,000 per cubic millimetre place the patient at risk for spontaneous haemorrhage. Platelets are produced in the bone marrow in increased quantities in response to stress.
(27 Sep 1997)
platelet endothelial cell activated protease <enzyme> Degrades casein and fibrinogen; secreted by endothelial cells and activated in the extracellular medium by platelets; not inhibited by serine protease inhibitors, metalloproteinase inhibitors, or cystein protease inhibitors; pH optimum 7.5
Registry number: EC 3.4.99.-
Synonym: pecap
(26 Jun 1999)
platelet function disorders <haematology> Platelet function can be affected by a number of different disease processes including polycythaemia vera, leukaemia, myelofibrosis, renal failure, multiple myeloma and some medications (for example penicillins, salicylates, phenothiazines).
Disturbed blood clotting can be manifested by: easy bruising, bleeding gums, nosebleeds, abnormal vaginal bleeding, rectal bleeding, skin rash, vomiting blood, coughing up blood or blood in the urine. A measure of bleeding time and coagulation profile will be part of the evaluation.
(31 Dec 1997)
platelet glycoprotein gpib-ix complex Platelet membrane glycoprotein complex essential for normal platelet adhesion and clot formation at sites of vascular injury. It is composed of three polypeptides, gpib alpha, gpib beta, and gpix. Glycoprotein ib functions as a receptor for von willebrand factor and for thrombin. Congenital deficiency of the gpib-ix complex results in bernard-soulier syndrome. The platelet glycoprotein gpv associates with gpib-ix and is also absent in bernard-soulier syndrome.
(12 Dec 1998)
platelet glycoprotein gpiib-iiia complex Platelet membrane glycoprotein complex important for platelet adhesion and aggregation. The complex is an integrin which recognises the arginine-glycine-aspartic acid (rgd) sequence present on several adhesive proteins. As such, it is a receptor for fibrinogen, von willebrand factor, fibronectin, vitronectin, and thrombospondin. A deficiency of gpiib-iiia results in glanzmann's thrombasthenia.
(12 Dec 1998)
platelet membrane glycoproteins Surface glycoproteins on platelets which have a key role in haemostasis and thrombosis such as platelet adhesion and aggregation. Many of these are receptors.
(12 Dec 1998)
platelet storage pool deficiency A group of disorders characterised by a decrease or lack of platelet dense bodies in which the releasable pool of adenine nucleotides and 5ht are normally stored.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • factor analysis
    ÀÎÀÚ ºÐ¼®
  • factor cost
    ¿äÀÎ(¿ä¼­)ºñ¿ë
  • intrinsic factor
    (»ýÈ­)³»À缺ÀÎÀÚ
  • nerve growth factor
    (»ý¸®)½Å°æ ¼ºÀåÀÎÀÚ(Áö°¢(±³°¨)½Å°æ¼¼Æ÷ÀÇ ¼ºÀåÀ» ÀÚ±ØÇÏ´Â ´Ü¹éÁú)
  • noise factor(figure)
    (ÁõÆø±â¿¡¼­ÀÇ)ÀâÀ½Áö¼ö
  • pp factor
    Ç× Æç¶ó±×¶ó ÀÎÀÚ(Æç¶ó±×¶ó ¿¹¹æ¿¡ ¾²´Â ´ÏÄÚÆ¾»ê,´ÏÄÚÆ¾»ê¸¶À̵å)
  • prime factor
    ¼ÒÀμö
  • releasing factor
    È£¸£¸ó ¹æÃâÀÎÀÚ
  • rheumatoid factor
    ·ù¸ÓƼÁòÀÎÀÚ(¸¸¼º °üÀý ·ù¸ÓƼÁò ȯÀÚÀÇ ÀÚ±â Ç×ü)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á